No Data
No Data
Mizuho Initiates Coverage On Doximity With Neutral Rating, Announces Price Target of $55
Is There Now An Opportunity In Doximity, Inc. (NYSE:DOCS)?
Are Medical Stocks Lagging Doximity (DOCS) This Year?
Jefferies Maintains Doximity(DOCS.US) With Buy Rating, Maintains Target Price $64
Robust Revenue Growth and Margin Expansion Lifted Doximity (DOCS) in Q3
Jefferies Maintains Doximity(DOCS.US) With Buy Rating, Raises Target Price to $64